Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small-molecule tyrosine-kinase inhibitor (TKI) of c-Met (HGFR) and VEGFR2, and also inhibits AXL, RET, and FLT3. It was discovered and developed by Exelixis Inc.
Read the full article on WikipediaStage IV renal cell carcinoma (RCC) Clinical criteria: Treatment Phase: Initial treatment The condition must be each of: (i) classified as having an intermediate to poor survival risk score according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), (ii) untreated with a tyrosine kinase inhibitor; OR Patient must have progressive disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) despite treatment with a tyrosine kinase inhibitor, irrespective of the current IMDC survival risk score, AND Patient must have a WHO performance status of 2 or less, AND The treatment must be the sole PBS-subsidised therapy for this condition. Treatment criteria: Patient must be undergoing treatment with this drug for the first time at the time of the first PBS prescription.
Locally advanced or metastatic differentiated thyroid cancer Clinical criteria: Treatment Phase: Initial treatment The condition must be refractory to radioactive iodine; OR Patient must be deemed ineligible for treatment with radioactive iodine, AND Patient must have progressive disease according to Response Evaluation Criteria in Solid Tumours (RECIST) whilst on treatment with a vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitor (TKI) for this indication; OR Patient must have developed intolerance of a severity necessitating permanent treatment withdrawal, in the absence of disease progression, to prior VEGF-targeted TKI therapy, AND Patient must have a WHO performance status of no higher than 2, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have thyroid stimulating hormone adequately suppressed. Radioactive iodine refractory is defined as: (i) a lesion without iodine uptake on a radioactive iodine (RAI) scan; or (ii) having received a cumulative RAI dose of greater than or equal to 600 mCi; or (iii) progression within 12 months of a single RAI treatment; or (iv) progression after two RAI treatments administered within 12 months of each other.
Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) or extra-pancreatic neuroendocrine tumour (epNET) Clinical criteria: Treatment Phase: Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition. Treatment criteria: Patient must not be undergoing treatment with this drug more than once per lifetime. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug. Patients who develop disease progression while receiving PBS-subsidised treatment with cabozantinib for this condition are not eligible to receive subsequent PBS-subsidised treatment with any of: (i) sunitinib, (ii) everolimus. Patients who develop intolerance while receiving PBS-subsidised treatment with cabozantinib are eligible to receive subsequent PBS-subsidised treatment with any of: (i) sunitinib, (ii) everolimus.
“110 hours”
Working under the parallel aged-care framework? Aged-care equivalent →